Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when
given together with azacitidine in treating patients with relapsed or refractory T-cell
lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Pierluigi Porcu
Collaborators:
Celgene Corporation Millennium Pharmaceuticals, Inc.